{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:14:45Z","timestamp":1792815285173,"version":"4.5.0"},"reference-count":48,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"16","content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2025,4,18]]},"abstract":"<jats:p>H3 K27\u2013altered spinal cord diffuse midline glioma (H3-SCDMG) poses therapeutic challenges. Analysis of 73 clinical samples revealed heightened proliferation in H3-SCDMG versus wild-type tumors, suggesting therapeutic vulnerabilities. Drug screening identified cytarabine (Ara-C) as highly effective in inhibiting proliferation in H3 K27M cell models, recently established patient-derived cells, and patient-derived xenograft models. Mechanistically, Ara-C can suppress tumor growth through DNA damage, cell-cycle arrest, and apoptosis. An investigator-initiated clinical trial involving four patients showed benefits in three cases. In addition, a subset of cells exhibited senescence and senescence-associated secretory phenotype post\u2013Ara-C treatment, accompanied by several immune checkpoint ligands\u2019 up-regulation and more immune cell infiltration. Combining Ara-C with dual Programmed cell death protein 1 (PD-1) and TIGIT blockade emerged as a promising strategy to disrupt immune evasion by senescent cells, enhancing antitumor responses. These findings highlight Ara-C\u2019s potential as a monotherapy and in synergy with immunotherapy for H3-SCDMG, offering potential strategies for clinical management.<\/jats:p>","DOI":"10.1126\/sciadv.adu3956","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:58:56Z","timestamp":1744826336000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":8,"title":["Ara-C suppresses H3 K27\u2013altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity"],"prefix":"10.1126","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0084-5891","authenticated-orcid":true,"given":"Bo","family":"Pang","sequence":"first","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SongYuan","family":"An","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-3491","authenticated-orcid":true,"given":"Yuzhou","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-9632","authenticated-orcid":true,"given":"Zheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Research Unit of Accurate Diagnosis, Treatment, and Translational Medicine of Brain Tumors, Chinese Academy of Medical Sciences, Beijing, China."},{"name":"Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9256-0176","authenticated-orcid":true,"given":"Fan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Research Unit of Accurate Diagnosis, Treatment, and Translational Medicine of Brain Tumors, Chinese Academy of Medical Sciences, Beijing, China."},{"name":"Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5138-8760","authenticated-orcid":true,"given":"Qing","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2893-9784","authenticated-orcid":true,"given":"Wenqing","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-6351","authenticated-orcid":true,"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."},{"name":"Research Unit of Accurate Diagnosis, Treatment, and Translational Medicine of Brain Tumors, Chinese Academy of Medical Sciences, Beijing, China."},{"name":"Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3276-6329","authenticated-orcid":true,"given":"Yongzhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."},{"name":"Research Unit of Accurate Diagnosis, Treatment, and Translational Medicine of Brain Tumors, Chinese Academy of Medical Sciences, Beijing, China."},{"name":"Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3451-8871","authenticated-orcid":true,"given":"Ruichao","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China."},{"name":"Research Unit of Accurate Diagnosis, Treatment, and Translational Medicine of Brain Tumors, Chinese Academy of Medical Sciences, Beijing, China."},{"name":"Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"217154","DOI":"10.1016\/j.canlet.2024.217154","article-title":"Understanding spinal cord astrocytoma: Molecular mechanism, therapy, and comprehensive management","volume":"601","author":"Pang B.","year":"2024","unstructured":"B. Pang, S. An, Y. Liu, T. Jiang, W. Jia, R. Chai, Y. Wang, Understanding spinal cord astrocytoma: Molecular mechanism, therapy, and comprehensive management. Cancer Lett. 601, 217154 (2024).","journal-title":"Cancer Lett."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/neuonc\/noad220","article-title":"H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions","volume":"26","author":"van den Bent M.","year":"2024","unstructured":"M. van den Bent, A. M. Saratsis, M. Geurts, E. Franceschi, H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions. Neuro Oncol. 26, S110\u2013S124 (2024).","journal-title":"Neuro Oncol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01205-w"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4750"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40478-020-00913-w","article-title":"The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation","volume":"8","author":"Chai R.-C.","year":"2020","unstructured":"R.-C. Chai, Y.-W. Zhang, Y.-Q. Liu, Y.-Z. Chang, B. Pang, T. Jiang, W.-Q. Jia, Y.-Z. Wang, The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathol. Commun. 8, 40 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232245"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.07.012"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/s41467-024-52973-4","article-title":"Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma","volume":"15","author":"Mbah N. E.","year":"2024","unstructured":"N. E. Mbah, A. L. Myers, P. Sajjakulnukit, C. Chung, J. K. Thompson, H. S. Hong, H. Giza, D. Dang, Z. C. Nwosu, M. Shan, S. R. Sweha, D. D. Maydan, B. Chen, L. Zhang, B. Magnuson, Z. Zhu, M. Radyk, B. Lavoie, V. N. Yadav, I. Koo, A. D. Patterson, D. R. Wahl, L. Franchi, S. Agnihotri, C. J. Koschmann, S. Venneti, C. A. Lyssiotis, Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma. Nat. Commun. 15, 8983 (2024).","journal-title":"Nat. Commun."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw0064"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"e13153","DOI":"10.1111\/bpa.13153","article-title":"Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma","volume":"33","author":"Chai R.-C.","year":"2023","unstructured":"R.-C. Chai, H. Yan, S.-Y. An, B. Pang, H.-Y. Chen, Q.-H. Mu, K.-N. Zhang, Y.-W. Zhang, Y.-Q. Liu, X. Liu, Z. Zhao, T. Jiang, Y.-Z. Wang, W.-Q. Jia, Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma. Brain Pathol. 33, e13153 (2023).","journal-title":"Brain Pathol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00401-023-02651-4","article-title":"A new subtype of diffuse midline glioma, H3 K27 and BRAF\/FGFR1 co-altered: A clinico-radiological and histomolecular characterisation","volume":"147","author":"Auffret L.","year":"2023","unstructured":"L. Auffret, Y. Ajlil, A. Tauzi\u00e8de-Espariat, T. Kergrohen, C. Puiseux, L. Riffaud, P. Blouin, A.-I. Bertozzi, P. Leblond, K. Blomgren, S. Froelich, A. Picca, M. Touat, M. Sanson, K. Beccaria, T. Blauwblomme, V. Dangouloff-Ros, N. Boddaert, P. Varlet, M.-A. Debily, J. Grill, D. Castel, A new subtype of diffuse midline glioma, H3 K27 and BRAF\/FGFR1 co-altered: A clinico-radiological and histomolecular characterisation. Acta Neuropathol. 147, 2 (2023).","journal-title":"Acta Neuropathol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00401-024-02800-3","article-title":"Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance","volume":"148","author":"Stegat L.","year":"2024","unstructured":"L. Stegat, A. Eckhardt, A. Gocke, S. Neyazi, L. Pohl, S. Schmid, M. Dottermusch, S. Frank, H. Pinnschmidt, J. Herms, M. Glatzel, M. Snuderl, L. Schweizer, C. Thomas, J. Neumann, M. M. Dorostkar, U. Sch\u00fcller, A. K. Wefers, Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance. Acta Neuropathol. 148, 40 (2024).","journal-title":"Acta Neuropathol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3171\/2024.6.SPINE24233","article-title":"Central nervous system dissemination in spinal cord astrocytomas: Association with H3 K27M mutation","volume":"41","author":"An S.","year":"2024","unstructured":"S. An, H. Lin, Y. Zhang, B. Pang, H. Yan, Y. Liu, L. Wang, Y. Wu, R. Chai, W. Jia, Y. Wang, Central nervous system dissemination in spinal cord astrocytomas: Association with H3 K27M mutation. J. Neurosurg. Spine 41, 716\u2013725 (2024).","journal-title":"J. Neurosurg. Spine"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff L. R.","year":"2022","unstructured":"L. R. Schaff, C. Grommes, Primary central nervous system lymphoma. Blood 140, 971\u2013979 (2022).","journal-title":"Blood"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3324\/haematol.2023.283275","article-title":"Central nervous system therapy in acute lymphoblastic leukemia: No more, no less","volume":"108","author":"Rives S.","year":"2023","unstructured":"S. Rives, Central nervous system therapy in acute lymphoblastic leukemia: No more, no less. Haematologica 108, 3193\u20133194 (2023).","journal-title":"Haematologica"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(10)70034-6","article-title":"Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours","volume":"11","author":"Beauchesne P.","year":"2010","unstructured":"P. Beauchesne, Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 11, 871\u2013879 (2010).","journal-title":"Lancet Oncol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100881"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1186\/s12885-024-12373-9","article-title":"Apatinib combined with temozolomide in diffuse midline glioma: A novel and effective therapy","volume":"24","author":"Li Y.-A.","year":"2024","unstructured":"Y.-A. Li, C. Zhao, J.-J. Ge, C. Li, F.-J. Xue, S.-P. Qi, C. Zhao, C.-C. Kong, J.-P. Zhang, Apatinib combined with temozolomide in diffuse midline glioma: A novel and effective therapy. BMC Cancer 24, 754 (2024).","journal-title":"BMC Cancer"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11060-024-04582-w","article-title":"Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: A systematic review","volume":"167","author":"Singh E.","year":"2024","unstructured":"E. Singh, M. E. Gurses, M. C. Costello, C. Berke, V. M. Lu, L. Daggubati, R. J. Komotar, M. E. Ivan, A. H. Shah, Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: A systematic review. J. Neurooncol 167, 39\u201347 (2024).","journal-title":"J. Neurooncol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun E.","year":"2020","unstructured":"E. Le Rhun, J. Wallet, A. Mailliez, M. C. Le Deley, I. Rodrigues, T. Boulanger, V. Lorgis, J. Barri\u00e8re, Y. M. Robin, M. Weller, J. Bonneterre, Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol. 22, 524\u2013538 (2020).","journal-title":"Neuro Oncol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41698-024-00541-w","article-title":"Sequencing of cerebrospinal fluid cell-free DNA facilitated early differential diagnosis of intramedullary spinal cord tumors","volume":"8","author":"Chai R.","year":"2024","unstructured":"R. Chai, S. An, H. Lin, B. Pang, H. Yan, Y. Liu, Y. Wu, L. Wang, X. Liu, H. Chen, X. Yang, Q. Chang, W. Jia, Y. Wang, Sequencing of cerebrospinal fluid cell-free DNA facilitated early differential diagnosis of intramedullary spinal cord tumors. NPJ Precis. Oncol. 8, 43 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","article-title":"Daunorubicin\/cytarabine liposome: A review in acute myeloid leukaemia","volume":"78","author":"Blair H. A.","year":"2018","unstructured":"H. A. Blair, Daunorubicin\/cytarabine liposome: A review in acute myeloid leukaemia. Drugs 78, 1903\u20131910 (2018).","journal-title":"Drugs"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-022-01755-2","article-title":"Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia","volume":"37","author":"Ling V. Y.","year":"2023","unstructured":"V. Y. Ling, J. Straube, W. Godfrey, R. Haldar, Y. Janardhanan, L. Cooper, C. Bruedigam, E. Cooper, P. Tavakoli Shirazi, S. Jacquelin, S.-K. Tey, J. Baell, F. Huang, J. Jin, Y. Zhao, L. Bullinger, M. J. Bywater, S. W. Lane, Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia. Leukemia 37, 143\u2013153 (2023).","journal-title":"Leukemia"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha S.","year":"2019","unstructured":"S. Jeha, D. Pei, J. Choi, C. Cheng, J. T. Sandlund, E. Coustan-Smith, D. Campana, H. Inaba, J. E. Rubnitz, R. C. Ribeiro, T. A. Gruber, S. C. Raimondi, R. B. Khan, J. J. Yang, C. G. Mullighan, J. R. Downing, W. E. Evans, M. V. Relling, C.-H. Pui, Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J. Clin. Oncol. 37, 3377\u20133391 (2019).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri A. J. M.","year":"2023","unstructured":"A. J. M. Ferreri, T. Calimeri, K. Cwynarski, J. Dietrich, C. Grommes, K. Hoang-Xuan, L. S. Hu, G. Illerhaus, L. Nayak, M. Ponzoni, T. T. Batchelor, Primary central nervous system lymphoma. Nat. Rev. Dis. Primers. 9, 29 (2023).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00794-7"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00705-7"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0007-y"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00449-4"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","article-title":"Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma","volume":"6","author":"Lin G. L.","year":"2018","unstructured":"G. L. Lin, S. Nagaraja, M. G. Filbin, M. L. Suv\u00e0, H. Vogel, M. Monje, Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol. Commun. 6, 51 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/neuonc\/noy145","article-title":"Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy","volume":"21","author":"Lieberman N. A. P.","year":"2019","unstructured":"N. A. P. Lieberman, K. DeGolier, H. M. Kovar, A. Davis, V. Hoglund, J. Stevens, C. Winter, G. Deutsch, S. N. Furlan, N. A. Vitanza, S. E. S. Leary, C. A. Crane, Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy. Neuro Oncol. 21, 83\u201394 (2019).","journal-title":"Neuro Oncol."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01226-x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"e163447","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: From tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta V. A.","year":"2023","unstructured":"V. A. Arrieta, C. Dmello, D. J. McGrail, D. J. Brat, C. Lee-Chang, A. B. Heimberger, D. Chand, R. Stupp, A. M. Sonabend, Immune checkpoint blockade in glioblastoma: From tumor heterogeneity to personalized treatment. J. Clin. Invest. 133, e163447 (2023).","journal-title":"J. Clin. Invest."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.013"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk0642"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00450-9"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.09.015"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa249"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4293"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.04.043"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40478-022-01336-5","article-title":"A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis","volume":"10","author":"Dhar S.","year":"2022","unstructured":"S. Dhar, S. Gadd, P. Patel, J. Vaynshteyn, G. P. Raju, R. Hashizume, D. J. Brat, O. J. Becher, A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis. Acta Neuropathol. Commun. 10, 47 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"e_1_3_2_46_2","first-page":"vdac018","article-title":"An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect","volume":"4","author":"Rahal F.","year":"2022","unstructured":"F. Rahal, C. Capdevielle, B. Rousseau, J. Izotte, J.-W. Dupuy, D. Cappellen, G. Chotard, M. M\u00e9nard, J. Charpentier, V. Jecko, C. Caumont, E. Gimbert, C. F. Grosset, M. Hagedorn, An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect. Neurooncol. Adv. 4, vdac018 (2022).","journal-title":"Neurooncol. Adv."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01236-3"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01124-z"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.04.020"}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.adu3956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:59:05Z","timestamp":1744826345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.adu3956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":48,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,4,18]]}},"alternative-id":["10.1126\/sciadv.adu3956"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.adu3956","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"2024-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"eadu3956"}}